2019 San Antonio Breast Cancer Symposium Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast cancer in women who discontinued…
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation…
Are patients enrolled in Medicare Advantage more or less likely to be prescribed high-cost drugs for cancer treatment compared with traditional Medicare? A new study…
Final data from the phase III TALAPRO-2 study show a significant improvement in overall survival in men with metastatic prostate cancer treated with a combination…
A recent ASCO survey measuring the impact of professional well-being and satisfaction on career plans among oncologists in the United States revealed a higher rate…
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed…
Patients with ERBB2-positive breast cancer and central nervous system (CNS) metastases only vs concomitant extracranial metastases have been found to experience longer overall survival but…
The results from the phase III FIRE-4 randomized clinical trial showed that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type-mutated metastatic colorectal cancer.…
As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan in patients…
Platinum-based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, defined as lasting at least 3 months.
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation…
